Doris Saltkill

Title: Innovations by Doris Saltkill in Pharmaceutical Development

Introduction

Doris Saltkill is a notable inventor based in Kansas City, MO, who has made significant contributions to the field of pharmaceuticals. With a total of three patents to her name, she has focused her work on improving treatments for patients with relapsing-remitting multiple sclerosis (RRMS). Her innovative approaches have the potential to enhance patient care and treatment efficacy.

Latest Patents

Doris Saltkill's latest patents include a reduced volume formulation of glatiramer acetate and methods of administration. One of her inventions outlines a method for reducing the frequency of relapses in a human patient afflicted with RRMS. This method involves administering 0.5 ml of an aqueous pharmaceutical solution containing 20 mg of glatiramer acetate and 20 mg of mannitol. Another patent focuses on an improved injection assisting device, which features an injection lock indicator designed to inform users about the locking state of the device. This indicator is strategically placed to contrast in color with the device's outer shells, enhancing usability and safety.

Career Highlights

Doris Saltkill is currently associated with Teva Pharmaceutical Industries Limited, where she continues to innovate in the pharmaceutical sector. Her work is characterized by a commitment to developing effective treatment solutions for chronic conditions, particularly in the realm of multiple sclerosis.

Collaborations

Doris has collaborated with notable colleagues such as Ayelet Altman and Tomer El-Gad, contributing to a dynamic team focused on advancing pharmaceutical technologies.

Conclusion

Doris Saltkill's contributions to pharmaceutical innovations, particularly in the treatment of multiple sclerosis, highlight her role as a leading inventor in the field. Her patents reflect a dedication to improving patient outcomes through innovative solutions.